Arrowhead Pharmaceuticals: UBS raises target price to $109 from $63
ARWR•UBS raised its target price for Arrowhead Pharmaceuticals to $109 from $63.
Related News
RedCloud announces shareholder meeting to vote on share consolidation
RCT•
Hershey: UBS cuts target price to $178 from $198
HSY•
Super Micro names former Western Digital executive Mark Long as new CFO
SMCI•
Church & Dwight Co Inc: UBS cuts target price to $106 from $107
CHD•
Manulife Financial target price raised to C$69 from C$67
MFC•